CPT 81424 Reimbursement Benchmarks & Policy

CPT code 81424 represents a comprehensive genetic testing panel for hereditary breast cancer-related disorders, including sequencing of at least 14 key genes such as BRCA1, BRCA2, and others. This code is nationally significant as it enables clinicians to assess genetic risk factors for breast and ovarian cancers, facilitating early detection and personalized care strategies. The service is typically performed in a laboratory setting and is a cornerstone in the management of patients with a family history or genetic susceptibility to these malignancies.

The publication provides an overview of coverage policies from major payers, with a focus on Blue Cross Blue Shield. Readers will gain insights into clinical benchmarks, policy updates, and the broader context of genetic testing for hereditary cancer syndromes. The analysis also highlights relevant ICD-10 diagnoses and related CPT codes, offering a comprehensive view of how this testing fits into current medical practice and billing workflows. This summary is designed for healthcare professionals, policy analysts, and laboratory administrators seeking to understand the clinical and reimbursement landscape for hereditary breast cancer genetic testing.

CPT Code Overview

CPT code 81424 is used for genetic testing related to hereditary breast cancer disorders. This code covers a genomic sequence analysis panel that must include sequencing of at least 14 genes, such as ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53. The service type is genetic testing, and the typical site of service is a laboratory (POS 81). This testing plays a critical role in identifying genetic susceptibility to breast and ovarian cancers, supporting clinical decision-making and patient management.

Clinical Context

A patient with a personal or family history suggestive of hereditary breast and ovarian cancer presents to their healthcare provider. The provider, often a specialist in medical genetics, evaluates the patient's risk factors and determines that comprehensive genetic testing is appropriate. The patient is referred for a genomic sequence analysis panel, which includes sequencing of at least 14 genes associated with hereditary breast cancer-related disorders (such as ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53). The testing is performed in a laboratory setting (Place of Service 81). Results are interpreted by a qualified genetics professional, and the findings are used to inform clinical management, genetic counseling, and potential preventive strategies for the patient and their family.

Coding Specifications

Modifier 26: Used to indicate the professional component of the service, such as interpretation of the genetic test results by a qualified provider.
Modifier : Used to denote a distinct procedural service, indicating that the genetic testing panel is separate from other procedures performed on the same day.

National mean rates for CPT code 81424 are identical between Blue Cross Blue Shield and BUCA (average commercial), both at $80.02. Medicare rates are not available in the input for comparison.

Rate dispersion is minimal across the commercial payers, with the 25th, 50th, and 75th percentiles all at $80.00. This indicates a very tight range, with no variation between the lower and upper quartiles for these payers.

The table and chart below present the full breakdown of national mean rates and percentile values for each payer.

Modifier Code	Description
`26`	Professional Component
`59`	Distinct Procedural Service

Taxonomy Code	Specialty Description
`207SG0201X`	Medical Genetics, Ph.D. Medical Genetics
`207SC0300X`	Medical Genetics, Clinical Genetics (M.D.)
`207SG0202X`	Medical Genetics, Clinical Biochemical Genetics
`207SG0203X`	Medical Genetics, Clinical Cytogenetics
`207SG0205X`	Medical Genetics, Clinical Molecular Genetics

Related Diagnoses

Z15.01: Genetic susceptibility to malignant neoplasm of breast
- Indicates the patient has a genetic predisposition to breast cancer, supporting the need for hereditary cancer panel testing.
C50.919: Malignant neoplasm of unspecified site of unspecified female breast
- Used when the patient has a diagnosis of breast cancer, which may prompt genetic testing to guide treatment and assess familial risk.
Z80.3: Family history of malignant neoplasm of breast
- Documents a family history of breast cancer, a key factor in determining eligibility for genetic testing.
Z84.81: Family history of carrier of genetic disease
- Indicates a family history of genetic disease carriers, relevant for assessing hereditary cancer risk.
Z31.5: Encounter for genetic counseling
- Used when the patient is seen for genetic counseling, often preceding or following genetic testing procedures.

Related CPT Codes

81211: BRCA1, BRCA2 gene analysis
- Used for targeted analysis of BRCA1 and BRCA2 genes, often as an initial screening or when a specific mutation is suspected.
81213: BRCA1, BRCA2 gene analysis, full sequence
- Provides comprehensive sequencing of BRCA1 and BRCA2 genes, typically used when a broader assessment is needed.
81214: BRCA1, BRCA2 gene analysis, known familial variants
- Used when testing for specific BRCA1 or BRCA2 variants already identified in the family.
81432: Hereditary breast cancer-related disorders, genomic sequence analysis panel
- Similar to 81424, but may differ in the number or type of genes included; often used as an alternative or in conjunction with 81424 depending on clinical indications.
81433: Hereditary breast cancer-related disorders, duplication/deletion analysis panel
- Used to detect large gene rearrangements (duplications/deletions) in breast cancer-related genes; commonly performed alongside sequence analysis panels for comprehensive assessment.

These codes are related to 81424 as they represent various approaches to genetic testing for hereditary breast cancer. Some are used together for a complete genetic workup, while others serve as alternatives based on patient history and clinical need.

National mean rates for CPT code 81424 are identical between Blue Cross Blue Shield and BUCA (average commercial), both at $80.02. Medicare rates are not available in the input for comparison.

The table and chart below present the full breakdown of national mean rates and percentile values for each payer.

OpenPayer

Summary & Overview

CPT 81424: Hereditary Breast Cancer Genetic Testing Panel